Former U.S. Covid-19 Vaccine Czar Returns $3.9 Million to Glaxo After Harassment Claim
(Bloomberg) -- Moncef Slaoui, the former U.S. Covid-19 vaccine czar fired by GlaxoSmithKline Plc after an internal investigation found he sexually harassed an employee several years ago, agreed to return about $3.9 million in cash to the U.K. drugmaker.
A company committee applied clawback provisions to retrieve funds from Slaoui after he was dismissed as chairman of Galvani Bioelectronics, a company controlled by Glaxo, according to the pharma giant's annual report published Friday.
About a year ago, Glaxo said that an investigation of Slaoui's conduct had substantiated allegations of harassment and inappropriate behavior, and in a letter to employees Chief Executive Officer Emma Walmsley wrote that Slaoui's actions represented an abuse of his leadership position and violated its policies and values.
Before he served as chief scientific adviser to the U.S. Operation Warp Speed program, Slaoui spent more than three decades working in the pharmaceutical industry, including as chairman of Glaxo's research and development and the head of its vaccine program.
In a March 2021 statement, Slaoui wrote that he apologized “unreservedly to the employee concerned” and was “deeply sorry for any distress caused.” On Friday, Slaoui couldn't immediately be reached for comment.
©2022 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
